AANEM 2025: Conference Review and Analysis for New Data on Emerging BAFF/APRIL Inhibitors for the Management of Patients with Generalized Myasthenia Gravis

Neurology Podcast

Credit(s)

1.0

AMA PRA Category 1 CreditTM

CPE Contact Hour

CNE Contact Hour

Pre-Test

Complete the pre-quiz poll to access the course episodes. 

Prequiz Podcast | MG-AANEM-25

Course Faculty

Marinos C Dalakas, MD
Marinos Dalakas, MD
Professor of Neurology
Director of the Neuromuscular Division
Thomas Jefferson University School of Medicine
Athens University Medical School
Philadelphia, Pennsylvania
Howard Headshot  e1721236596371
James F. Howard Jr., MD
Professor of Neurology & Medicine
The University of North Carolina School of Medicine
Chapel Hill, North Carolina
Pushpa Narayanaswami, MD, FAAN
Pushpa Narayanaswami, MD, FAAN
Professor of Clinical Neurology
Harvard Medical School
Vice Chair, Clinical Operations
Department of Neurology
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty

have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.

Faculty Relationship Identified With:
James F. Howard Jr., MD Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Amgen Inc.; argenX; AstraZeneca; Biohaven Ltd; Cartesian Therapeutics; CorEvitas, LLC; Curie.Bio; EMD Serono; F. Hoffmann-LaRoche Ltd; H. Lundbeck A/S; Hansa Biopharma; Horizon Therapeutics Plc; Merck & Co., Inc.; NMD Pharma; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi, US; Seismic Therapeutics; TG Therapeutics; Toleranzia AB; UCB Biosciences; Viela Bio

Grant/Research Support: Ad Scientiam; Alexion Pharmaceuticals, Inc.; argenX; AstraZeneca; Cartesian Therapeutics; EMD Serono; Merck & Co., Inc.; NMD Pharma; Ra Pharmaceuticals; UCB Biosciences

Speaker's Bureau: Alexion Pharmaceuticals, Inc.; Amgen Inc.; argenX; AstraZeneca; Biohaven Ltd; Cartesian Therapeutics; CorEvitas, LLC; Curie.Bio; EMD Serono; F. Hoffmann-LaRoche Ltd; H. Lundbeck A/S; Hansa Biopharma; Horizon Therapeutics Plc; Merck & Co., Inc.; NMD Pharma; Novartis Pharmaceuticals Corporation; Ra Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi, US; Seismic Therapeutics; TG Therapeutics; Toleranzia AB; UCB Biosciences; Viela Bio

Pushpa Narayanaswami, MD, FAAN Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Amgen; argenX; CVS; Cartesian Therapeutics; Dianthus Therapeutics; EMD Serono; Immuneabs; Immunovant, Inc.; Johnson & Johnson; UCB Biosciences; Viridian Therapeutics, Inc.

Grant/Research Support: Alexion Pharmaceuticals, Inc.; argenX; Caballetta Bio, Inc.; Dianthus Therapeutics; NMD Pharma; Sanofi, US

Marinos Dalakas, MD

 

Consultant/Advisor: Adicet Bio; Amgen; argenX; Dysimmune Diseases Foundation; Grifols, S.A.; Shoreline Biosciences

 

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC, Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour, including 1.0 Pharmacotherapeutic Contact Hour (Provider #P0491).

AcademicCME designates this continuing education activity for 1.0 CPE Contact Hour (0.10 CEUs) of continuing pharmacy education credit (JA4008190-0000-25-034-H01-P).

Participants should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an independent educational grant from Vor Bio.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Vor Bio do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

For all CE inquiries or special needs, please contact admin@academiccme.com.

ACCREDIDATION

Earn your Credits After Completing Podcast Episodes

Related Podcast Courses

np microphone 888718 0E193A 1
Neurology
Review of McDonald Criteria 2024 Updates for the Management of Patients with Multiple Scle...
np microphone 888718 0E193A 1
Neurology
A Scientific and Practical Guide to the Administration and Monitoring of FcRn Blockers for...
np microphone 888718 0E193A 1
Neurology
Advances in Disease Management of Generalized Myasthenia Gravis by Reducing Levels of IgG ...